Locteron Phase 2a Clinical Results

We have completed a 12-week, Phase 2a clinical trial (SELECT-1) in Europe to evaluate four different doses of Locteron administered once every two weeks in combination with ribavirin in 32 treatment-naïve hepatitis C patients. In this trial, an early virologic response was achieved by 100% (16/16) of patients treated with the two highest doses, 480 and 640 µg, and by 88% (7/8) of patients treated with the 320 µg dose. In addition, patients receiving Locteron experienced fewer and less severe side effects than those previously reported for the currently marketed interferons, Pegasys and PEG-Intron, and for Albuferon, an interferon product currently under development. Accordingly, the objective of this trial has been met as we have identified a range of doses with an appropriate combination of viral reduction and favorable tolerability to proceed to a Phase 2b trial.

	Active agent (interferon produced in LEX System) Demonstrated equivalents to IntronA
	Presented at 2006 EASL conference Highlighted tolerability advantage versus PEG-Intron

Return to top